World Therapeutic Apheresis Market

World Therapeutic Apheresis Market

This report analyzes the US market for Therapeutic Apheresis in US$ Thousand. The specific procedures analyzed are Plasmapheresis, Immunoadsorption, Erythrocytapheresis, Plateletpheresis, Leukapheresis, Photopheresis, and Lipidpheresis. The specific end-use segments analyzed are Neurology Disorders, Hematology & Oncology Disorders, Rheumatology Disorders, and Others. The report provides separate comprehensive analytics for the US. Annual forecasts are provided for US region for the period of 2000 through 2015. The report profiles 19 companies including many key and niche players such as Baxter Healthcare Corporation, CaridianBCT, Inc., Fenwal, Inc., Fresenius Medical Care North America, Haemonetics Corporation, HemaCare Corporation, Hospital Clinical Services Group, Inc., and Therakos,, Inc. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

THERAPEUTIC APHERESIS MCP-1237
A US MARKET REPORT


CONTENTS


I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations I-1
Disclaimers I-2
Data Interpretation & Reporting Level I-2
Quantitative Techniques & Analytics I-3
Product Definitions and Scope of Study I-3
A Peek into the Above-Mentioned Procedures I-3
Plasmapheresis I-3
Immunoadsorption I-4
Erythrocytapheresis I-4
Plateletpheresis I-4
Leukapheresis I-4
Photopheresis I-4
Lipidpheresis I-4


II. A US MARKET REPORT

1. Market Analysis II-1
A Current & Future Analysis II-1
A Promising Outlook II-1

2. Market Trends II-3
Apheresis Process Leads to Rise in Platelet Donors II-3
Therapeutic Apheresis Devices - A Perplexing Market II-3
Plateletpheresis: The Treatment of Choice for Patients II-3
Photopheresis Market Growing at a High Rate II-3
Vendors’ Attitude Hampers Growth Prospects of Therapeutic
Apheresis II-4
Developing New Applications for Therapeutic Apheresis is the
Need of the Hour II-4
CFA - An Effective Way to Pull Up Cold Hemagglutinin Disease II-5

3. Competitive Scenario II-6
Overview II-6
Technology: The Only Key for Success II-6
CaridianBCT: The World Leader II-6
Market Share Trends in the Recent Past II-7
By Procedures (Revenues) II-7
Table 1: US Market for Therapeutic Apheresis (2002 & 2005):
Percentage Breakdown of Revenues by Company for Gambro BCT,
Therakos, Fresenius Hemocare, Kaneka Pharma America
Corporation, Baxter Transfusion Therapies, and Others
(includes corresponding Graph/Chart) II-7
By Procedures (Number of Procedures) II-8
Table 2: US Market for Therapeutic Apheresis (2002 & 2005):
Percentage Breakdown of Number of Procedures by Company for
Gambro BCT, Therakos, Fresenius HemoCare, Haemonetics,
Baxter Transfusion Therapies, and Others (includes
corresponding Graph/Chart) II-8
By Neurology Disorders (Revenues) II-8
Table 3: US Market for Therapeutic Apheresis in
Neurological Disorders (2002 & 2005): Percentage Breakdown
of Revenues by Company for Gambro BCT, Fresenius HemoCare,
Haemonetics, and Others (includes corresponding Graph/Chart) II-9
By Neurology Disorders (Number of Procedures) II-9
Table 4: US Market for Therapeutic Apheresis in Neurological
Disorders (2002 & 2005): Percentage Breakdown of Number of
Procedures by Company for Gambro BCT, Fresenius HemoCare,
Haemonetics, and Others (includes corresponding Graph/Chart) II-9
By Hematology and Oncology Disorders (Revenues) II-10
Table 5: US Market for Therapeutic Apheresis in Hematology
and Oncology Disorders (2002 & 2005): Percentage Breakdown
of Revenues by Company for Gambro BCT, Therakos, Fresenius
HemoCare, Baxter Transfusion Therapies, and Others (includes
corresponding Graph/Chart) II-10
By Hematology and Oncology (Number of Procedures) II-11
Table 6: US Market for Therapeutic Apheresis in Hematology
and Oncology Disorders in (2002 & 2005): Percentage
Breakdown of Number of Procedures by Company for Gambro BCT,
Fresenius HemoCare, Baxter Transfusion Therapies, Therakos,
and Others (includes corresponding Graph/Chart) II-11

4. Market Overview & Outlook II-12
Market Drivers II-12
New Reimbursement Policies Create Growth Opportunities for
Therapeutic Apheresis II-12
Increased Industry Consolidation Drives Research II-12
Development of New Technology II-13
Research Unveils Novel Applications II-13
Market Restraints II-13
Lack of Awareness Restrains Growth II-13
Therapeutic Apheresis Costs Still a Concern II-13
Market Challenges II-13
Development of Inexpensive Apheresis Therapy II-13
Scarcity of Qualified Donors II-14
Pediatry: An Untapped Opportunity II-14

5. Regulatory Environment II-15

6. Product Overview II-16
Therapeutic Apheresis: An Introduction II-16
Overview of Therapeutic Apheresis II-16
Blood Components II-16
Apheresis and Therapeutic Apheresis: The Difference II-17
Therapeutic Apheresis Process II-17
Duration, Frequency, and Efficiency of Therapeutic Apheresis II-17
Segregation of Blood Components II-17
Centrifugation II-17
Filtration II-18
History II-18
Kinds of Therapeutic Apheresis Procedures II-18
Plasmapheresis II-19
Erythrocytapheresis II-19
Plateletpheresis II-19
Leukapheresis II-19
Stem Cell Apheresis II-19
Photopheresis II-19
Lipidpheresis II-20
Cytapheresis II-20
Immunoadsorption II-20
Rheopheresis II-20
Therapeutic Apheresis is Remedial for Various Diseases II-20

7. Product Trends and Issues II-22
Therapeutic Plasmapheresis with Fresh Frozen Plasma (FFP)
Replacement II-22
Risks Associated with Therapeutic Apheresis II-22
Categories of Indications for Therapeutic Apheresis II-22
Plasma Exchange and Plasmapheresis: The Difference II-23
Applications of Plasma Exchange II-23
Chronic Diseases II-23
Acute Self-Limited Disease II-24
Emerging Applications II-24

8. Technological Developments in Recent Past II-25
HemoCleanse to Develop Novel Plasmapheresis Device II-25
Aethlon Develops a New Device to Remove HIV II-25
Therapeutic Plasmapheresis for Treatment of Autoimmune Diseases II-25
Occulogix Offers Blood-Filtering Treatment for Macular
Degeneration II-26

9. Recent Industry Activity II-27
Gambro to Change Name to CaridianBCT II-27
Therakos Obtains CE Mark in Europe II-27
Baxter Divests Transfusion Therapies Business II-27
SCSG Gets Hold of Fresenius Medical Care Extracorporeal Alliance II-27
Rheologics Technologies Takes Over Cardiodyne Electronics II-27
Biotest Obtains Business Unit of Nabi BioPharmaceuticals II-28
Gambro BCT Receives FDA Clearance for Spectra OptiaSystem II-28
MedaSorb Receives Rights for Blood Processing II-28
Fresenius Medical Care Takes Over Renal Care II-28
Haemonetics Signs Acquisition Agreement with Arryx II-29
Cerus Receives Rights for INTERCEPT Blood System II-29
Blood Systems to Implement Gambro BCT 7-day platelets II-29

10. Strategic Corporate Developments in Recent Past II-30
Renal Care Pockets Bay Area Mobile Apheresis Program. II-30
Haemonetics Pacts with FMCEA II-30
PhereSys and ACGT Ink Consulting Services Pact II-30
CHF Forges a Service Provider Pact with FMCEA II-30
Otsuka America Inks a Pact with HemaCare II-31
Gambro Acquires Ivex II-31
Fresenius HemoCare Becomes a Part of Fresenius Kabi II-31
Alpha Therapeutic Sells Assets to Probitas Pharma and Baxter II-31
Gambro Signs Agreement with The American Red Cross II-31
Gambro Receives Contract from NBS II-31
FMC-EA Inks with Allina Hospitals II-31
Gambro Starts a New Company, Navigant Biotechnologies II-32
Gambro’s Vista™ Receives Approval from FDA II-32
Gambro’s New Anticoagulant Solution Receives FDA Approval II-32
Gambro BCT Receives FDA Clearance for New Filter Tubing Sets
Developed by Pall II-32
Gambro Launches Trima Accel Automated Blood Collection System II-33
Fresenius HemoCare Acquires PROSORBA® Column from Cypress
Bioscience II-33
Gambro Buys the Assets of Sanguistech II-33
Haemonetics Inks Purchase Agreement with Alpha Therapeutic Corp II-33
Gambro Joins Forces with the Walter Reed Army Institute of
Research II-33
Gambro Collaborates with Dendreon for Commercialization of
Therapeutic Vaccines II-34
Gambro AB Enters into a Partnership with Sangart II-34
WakeMed Awards a Contract to HemaCare’s Subsidiary II-34
HemaCare’s Subsidiary Coral in Agreement with CMH II-34
BioTransplant Inks an Exclusive Distribution Agreement with
Gambro BCT II-34
Gambro BCT Receives US Patent for its Pathogen Inactivation
Technology II-35
Gambro’s Trima Receives Approval of The Japanese Red Cross
Society II-35
Gambro BCT Test Launches the Vista™ Information System II-35
HemaCare Enters into a Partnership with LBMMC II-35

11. Focus on Select Players II-36
Baxter Healthcare Corporation II-36
CaridianBCT, Inc. II-36
Fenwal, Inc. II-36
Fresenius Medical Care North America (FMCNA) II-36
Haemonetics Corporation II-37
HemaCare Corporation II-37
Hospital Clinical Services Group, Inc. (HCSG) II-37
Therakos, Inc. II-38

12. Market Perspective II-39
Table 7: US Recent Past, Current & Future Market Analysis for
Therapeutic Apheresis by Procedure - Plasmapheresis,
Immunoadsorption, Erythrocytapheresis, Plateletpheresis,
Leukapheresis, Photopheresis and Lipidpheresis Markets
Independently Analyzed with Annual Revenues in US$ Thousand
for Years 2000 through 2010 (includes corresponding
Graph/Chart) II-39

Table 8: US Long-Term Projections for Therapeutic Apheresis
by Procedure - Plasmapheresis, Immunoadsorption,
Erythrocytapheresis, Plateletpheresis, Leukapheresis,
Photopheresis and Lipidpheresis Markets Independently Analyzed
with Annual Revenues in US$ Thousand for Years 2011 through
2015 (includes corresponding Graph/Chart) II-39

Table 9: US 10-Year Perspective for Therapeutic Apheresis by
Procedure - Percentage Breakdown of Revenues for
Plasmapheresis, Immunoadsorption, Erythrocytapheresis,
Plateletpheresis, Leukapheresis, Photopheresis and
Lipidpheresis Markets Independently Analyzed for 2003, 2008 &
2012 (includes corresponding Graph/Chart) II-40

Table 10: US Recent Past, Current & Future Market Analysis
for Therapeutic Apheresis by End Use - Neurology Disorders,
Hematology and Oncology Disorders, Rheumatology Disorders and
Other Markets Independently Analyzed with Annual Revenues in
US$ Thousand for Years 2000 through 2010 (includes
corresponding Graph/Chart) II-41

Table 11: US Long-Term Projections for Therapeutic Apheresis
by End Use - Neurology Disorders, Hematology and Oncology
Disorders, Rheumatology Disorders and Other Markets
Independently Analyzed with Annual Revenues in US$ Thousand
for Years 2011 through 2015 (includes corresponding
Graph/Chart) II-41

Table 12: US 10-Year Perspective for Therapeutic Apheresis by
End Use - Percentage Breakdown of Revenues for Neurology
Disorders, Hematology and Oncology Disorders, Rheumatology
Disorders and Other Markets Independently Analyzed for 2003,
2008 & 2012 (includes corresponding Graph/Chart) II-42


III. COMPETITIVE LANDSCAPE